150 related articles for article (PubMed ID: 35535108)
1. Changes in Serum Interferon Gamma and Interleukin-10 in Relation to Direct-Acting Antiviral Therapy of Chronic Hepatitis C Genotype 4: A Pilot Study.
Nabeel MM; Darwish RK; Alakel W; Maher R; Mostafa H; Hashem A; Elbeshlawy M; Abul-Fotouh A; Shousha HI; Saeed Marie M
J Clin Exp Hepatol; 2022; 12(2):428-434. PubMed ID: 35535108
[TBL] [Abstract][Full Text] [Related]
2. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients.
Elsharkawy A; Eletreby R; Fouad R; Soliman Z; Abdallah M; Negm M; Mohey M; Esmat G
Expert Rev Gastroenterol Hepatol; 2017 Aug; 11(8):773-778. PubMed ID: 28480808
[TBL] [Abstract][Full Text] [Related]
3. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
[TBL] [Abstract][Full Text] [Related]
4. Increased peripheral CD4
Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
[TBL] [Abstract][Full Text] [Related]
5. Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C.
Saraiva GN; do Rosário NF; Medeiros T; Leite PEC; Lacerda GS; de Andrade TG; de Azeredo EL; Ancuta P; Almeida JR; Xavier AR; Silva AA
Mediators Inflamm; 2018; 2018():8578051. PubMed ID: 29977152
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
Najafi Fard S; Schietroma I; Corano Scheri G; Giustini N; Serafino S; Cavallari EN; Pinacchio C; De Girolamo G; Ceccarelli G; Scagnolari C; Vullo V; d'Ettorre G
Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):319-329. PubMed ID: 29279268
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Goel A; Bhargava R; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
[TBL] [Abstract][Full Text] [Related]
8. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
De Pace V; Morelli MC; Ravaioli M; Maggi F; Galli S; Vero V; Re MC; Cescon M; Pistello M
New Microbiol; 2019 Oct; 42(4):189-196. PubMed ID: 31609453
[TBL] [Abstract][Full Text] [Related]
10. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa.
Cacciarelli TV; Martinez OM; Gish RG; Villanueva JC; Krams SM
Hepatology; 1996 Jul; 24(1):6-9. PubMed ID: 8707283
[TBL] [Abstract][Full Text] [Related]
11. Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India.
Gupta V; Kumar A; Sharma P; Tyagi P; Bansal N; Singla V; Arora A
J Clin Exp Hepatol; 2014 Dec; 4(4):287-92. PubMed ID: 25755575
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial).
Marcellin F; Mourad A; Lemoine M; Kouanfack C; Seydi M; Carrieri P; Attia A; Protopopescu C; Lacombe K; Boyer S
JHEP Rep; 2023 Mar; 5(3):100665. PubMed ID: 36686592
[TBL] [Abstract][Full Text] [Related]
13. Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy.
Farcomeni S; Moretti S; Fimiani C; Sulekova LF; Vescio F; Sernicola L; Maggiorella MT; Remoli AL; Picconi O; Mosca L; Esvan R; Biliotti E; Ciccozzi M; Sgarbanti M; Taliani G; Borsetti A
Pathogens; 2021 Nov; 10(11):. PubMed ID: 34832642
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-Thalassemia Major.
Mehta R; Kabrawala M; Nandwani S; Desai P; Bhayani V; Patel S; Parekh V
J Clin Exp Hepatol; 2018 Mar; 8(1):3-6. PubMed ID: 29743790
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.
Ji D; Chen GF; Niu XX; Zhang M; Wang C; Shao Q; Wu V; Wang Y; Cheng G; Hurwitz SJ; Schinazi RF; Lau G
Metabol Open; 2021 Jun; 10():100090. PubMed ID: 33889834
[TBL] [Abstract][Full Text] [Related]
16. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
17. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement.
Tag-Adeen M; Sabra AM; Akazawa Y; Ohnita K; Nakao K
Hepat Med; 2017; 9():45-53. PubMed ID: 29062242
[TBL] [Abstract][Full Text] [Related]
18. Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantation.
Wu SH; Loong CC; Chu CJ; Su CW; Lin CC; Hsia CY; Liu C; Lee SD; Wang YJ; Lee FY; Linb NC; Chen CY; Huang YH; Hou MC
J Chin Med Assoc; 2020 Jan; 83(1):18-24. PubMed ID: 31714442
[TBL] [Abstract][Full Text] [Related]
19. Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy.
Kostadinova L; Shive CL; Zebrowski E; Fuller B; Rife K; Hirsch A; Compan A; Moreland A; Falck-Ytter Y; Popkin DL; Anthony DD
Pathog Immun; 2018 Sep; 3(1):149-163. PubMed ID: 30370392
[TBL] [Abstract][Full Text] [Related]
20. Effect of Direct Acting Antivirals (DAAs) on Myeloid-Derived Suppressor Cells Population in Egyptian Chronic Hepatitis C Virus Patients: A Potential Immunomodulatory Role of DAAs.
Abdulsamad B; Afifi M; Awaad AK; Elbendary W; Mustafa H; Elsherbini B
Viral Immunol; 2023 May; 36(4):259-267. PubMed ID: 36802279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
